This PDF 1.5 document has been generated by Microsoft® Word for Office 365 / ABBYY FineReader 12, and has been sent on pdf-archive.com on 17/01/2020 at 06:56, from IP address 92.253.x.x.
The current document download page has been viewed 223 times.
File size: 241.66 KB (3 pages).
Privacy: public file
ESMO-THE CHRISTIE
PRECEPTORSHIP PROGRAMME
LUNG CANCER
Multidisciplinary management, standards of care and future perspectives
Manchester, United Kingdom
11-13 March 2020
CO-CHAIRS:
Fiona Blackhall, United Kingdom
Enriqueta Felip, Spain
Raffaele Califano, United Kingdom
LEARNING OBJECTIVES
To
To
To
To
To
To
To
To
learn about the evidence-base for lung cancer screening and novel diagnostic modalities
learn about the management of early stage NSCLC and use of adjuvant treatments
understand the role of m ulti-m odality treatment in locally advanced NSCLC and limited stage SCLC
learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC
understand the role of im m une-checkpoint blockade for lung cancer and to learn about novel im munotherapies
learn about treatment of NSCLC with oligom etastatic disease
learn about the systemic treatment of mesothelioma and SCLC
learn about the role of supportive and palliative care for thoracic malignancies
Wednesday, 11 March 2020
08:15-09:15
60’
Registration
09:15-10:55
100
SESSION 1
Screening and diagnostics for lung cancer
40’
Lung cancer screening
Chairs:
Enriqueta Felip, ES
Raffaele Califano, UK
Haval Balata, UK
30’
EBUS TBNA in diagnosis/staging of lung cancer
Richard Booton, UK
30’
Role of pathologist in diagnosis and mutation analysis of lung
cancer
Keith M. Kerr, UK
’
Coffee break
11:20-12:20
60’
SESSION 1 - cont.
Screening and diagnostics for lung cancer
30’
PET/CT in staging of lung cancer
30’
Medical thoracoscopy in the management of thoracic
malignancies
12:20-13:40
Chairs:
Fiona Blackhall, UK
Raffaele Califano, UK
Rohit Kochhar, UK
Lunch
30’
Surgery for early stage NSCLC
Chairs:
Giulia Veronesi, IT
Cecile Le Pechoux, FR
Giulia Veronesi, IT
30’
Stereotactic ablative RT for early stage NSCLC
Suresh Senan, NL
SESSION 2
Radical treatment of early stage NSCLC
14:40-15:00
Coffee break
30’
Adjuvant radiotherapy for completely resected early stage
NSCLC
Cecile Le Pechoux, FR
30’
Adjuvant chemotherapy for resected early stage NSCLC
Paul Taylor, UK
Close of day 1
Chairs:
Fiona Blackball, UK
Raffaele Califano, UK
16:00-16:10
10
’
Thursday, 12 March 2020
30’
1st line chemotherapy for advanced NSCLC
Chairs:
Fiona Blackball, UK
Martin Reck, DE
David Planchard, FR
30’
1st line Im m une-checkpoint blockade for NSCLC
Luis Paz-Ares, ES
30’
2nd line treatment for advanced NSCLC
M artin Reck, DE
09:05-10:35
90’
10:35-12:55
120
’
SESSION 3 - cont.
Advanced NSCLC
SESSION 3 - cont.
Advanced NSCLC
Treatment of EGFR mutant advanced NSCLC
Chairs:
Fiona Blackball, UK
Yvonne Summers, UK
Raffaele Califano, UK
Coffee break
Treatment of ALK/R0S1 positive advanced NSCLC
Fiona Blackhall, UK
Maintenance treatment for advanced NSCLC
Yvonne Summers, UK
Beyond A LK/R 0S 1 and EGFR: Novel m olecularly driven
targeted therapies in NSCLC
Simon Ekman, SE
Lunch
30’
Systemic treatment of mesothelioma
Chairs:
Enriqueta Felip, ES
Paul Baas, NL
Paul Baas, NL
30’
Treatment of oligom etastatic NSCLC
Anne-M arie C. Dingemans, NL
14:00-15:00
60’
SESSION 4
Palliative treatment of lung cancer and mesothelioma
Coffee break
15:30-16:30
60’
SESSION 4 -co n t.
Palliative treatment of lung cancer and mesothelioma
Chairs:
Raffaele Califano, UK
Tora S. Solheim , NO
Catherine McBain, UK
30’
Radical treatment of brain metastases: The importance of a
neuro-oncology m ulti-disciplinary approach
30’
Supportive and palliative care in lung cancer
Karin Jordan, DE
16:30-16:35
5’
Close of day 2
Chairs:
Fiona Blackball, UK
Raffaele Califano, UK
19:00
Welcome drink
19:30
Dinner
Friday, 13 March 2020
30’
Treatment of locally advanced NSCLC in the elderly
Chairs:
Fiona Blackball, UK
Paul E. V an S ch il, BE
David W oolf, UK
30’
Combined m odality treatment for NSCLC with N2 disease
Clara Chan, UK
30’
Role of surgery for N2 disease
Paul E. Van Schil, BE
09:10-10:40
90’
SESSION 5
Locally advanced NSCLC
10:40-11:00
Coffee break
11:00-12:00
60’
SESSION 5 - cont.
Locally advanced NSCLC
60’
Participants clinical case discussion (3x20’)
Chairs:
Corinne Faivre-Finn, UK
Paul E. V an S ch il, BE
Faculty
Each 20 min slot for clinical case discussion includes 10’ case presentation and 10’ Q&A / interactive panel discussion
12:00-13:00
Lunch
13:00-15:00
120
SESSION 6
SCLC
’
Treatment of limited stage SCLC
Chairs:
Corinne Faivre-Finn, UK
Enriqueta Felip, ES
Corinne Faivre-Finn, UK
Chemotherapy for extensive stage SCLC
M artin Friih, CH
Immune checkpoint blockade for SCLC
Pilar Garrido Lopez, ES
Targeted agents in SCLC
Enriqueta Felip, ES
Coffee break
15:15-16:15
60’
SESSION 6 - cont.
SCLC
Chairs:
Enriqueta Felip, ES
Raffaele Califano, UK
Neil Bayman, UK
30’
Prophylactic cranial irradiation and role of thoracic RT for
extensive stage SCLC
30’
Cellular immunotherapy
Fiona Thistlethwaite, UK
Conclusion and farewell
Raffaele Califano, UK
16:15-16:20
5’
ESMO-Preceptorship-on-Lung-Cancer-Manchester-2020-Programme.ocr.pdf (PDF, 241.66 KB)
Use the permanent link to the download page to share your document on Facebook, Twitter, LinkedIn, or directly with a contact by e-Mail, Messenger, Whatsapp, Line..
Use the short link to share your document on Twitter or by text message (SMS)
Copy the following HTML code to share your document on a Website or Blog